Abstract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Combretum laurifolium Mart. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Combretum laurifolium Mart. suspended in the vehicle. A method of making an extract of Combretum laurifolium Mart. may comprise creating a component solution by treating Combretum laurifolium Mart. material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Combretum laurifolium Mart. may comprise components extracted using various solvents.

Abstract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Combretum laurifolium Mart. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Combretum laurifolium Mart. suspended in the vehicle. A method of making an extract of Combretum laurifolium Mart. may comprise creating a component solution by treating Combretum laurifolium Mart. material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Combretum laurifolium Mart. may comprise components extracted using various solvents.

Abstract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Combretum laurifolium Mart. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Combretum laurifolium Mart. suspended in the vehicle. A method of making an extract of Combretum laurifolium Mart. may comprise creating a component solution by treating Combretum laurifolium Mart. material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Combretum laurifolium Mart. may comprise components extracted using various solvents.

Abstract: The present invention is a novel nutritional product composition, formulated to be used as medical foods for managing blood flow related problems. The formula comprises clary sage root extract highly enriched for Tanshinones L-arginine, niacin, vitamin C, Vitamin B6, vitamin B12, folate and soy isoflavones. The composition enhances the increased blood flow to the muscle mass. Tanshinone IIA is an inducer of heme oxygenase 1 and suppressor of the induction of inducible nitric oxide synthase, which could result in desirable effects on two important gaseous signaling molecules, namely carbon monoxide and nitric oxide that have significant anti-inflammatory properties.

Abstract: The present invention is a novel nutritional product composition formulated to be used as medical foods for managing COPD. The formula comprises clary sage root extract, L-Leucine, L-Isoleucine, L-Valine and L-Glutamine. The most active chemicals that import antioxidants proprieties are Tanshinones. The composition enhances the activity of Phase 2 enzymes that deactivate and react to oxygen species and many toxins present in tobacco smoke. Preparation of highly enriched Tanshinones improved the lung function in patients with chronic asthmatic bronchitis.

Abstract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Combretum laurifolium Mart. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Combretum laurifolium Mart. suspended in the vehicle. A method of making an extract of Combretum laurifolium Mart. may comprise creating a component solution by treating Combretum laurifolium Mart. material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Combretum laurifolium Mart. may comprise components extracted using various solvents.

Abstract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Combretum laurifolium Mart. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Combretum laurifolium Mart. suspended in the vehicle. A method of making an extract of Combretum laurifolium Mart. may comprise creating a component solution by treating Combretum laurifolium Mart. material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Combretum laurifolium Mart. may comprise components extracted using various solvents.

Abstract: The present invention relates to the use of triterpenes of the formula (I): which are inhibitors of nuclear factor kappa B (NF-?B for use in the treatment of inflammatory diseases and for cancers susceptible to an NF-?B inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.

Abstract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Combretum laurifolium Mart. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Combretum laurifolium Mart. suspended in the vehicle. A method of making an extract of Combretum laurifolium Mart. may comprise creating a component solution by treating Combretum laurifolium Mart. material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Combretum laurifolium Mart. may comprise components extracted using various solvents.

Abstract: The present invention is a method of growing and harvesting forskohlin-containing cultivars of the Coleus plant in North America and other geographic areas that results in increased yield of the phytochemical forskohlin per plant, as well as increasing rhizome and root biomass.

Abstract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Combretum laurifolium Mart. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Combretum laurifolium Mart. suspended in the vehicle. A method of making an extract of Combretum laurifolium Mart. may comprise creating a component solution by treating Combretum laurifolium Mart. material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Combretum laurifolium Mart. may comprise components extracted using various solvents.

Abstract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Spondias mombin L. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Spondias mombin L. suspended in the vehicle. A method of making an extract of Spondias mombin L. may comprise creating a component solution by treating Spondias mombin L. material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Spondias mombin L. may comprise components extracted using various solvents.

Abstract: The present invention relates to the use of triterpenes of the formula (I): which are inhibitors of nuclear factor kappa B (NF-KB for use in the treatment of inflammatory diseases and for cancers susceptible to an NF-KB inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.

Abstract: The present invention relates to the use of certain novel compositions from wax myrtle (Morella cerifera) which are inhibitors of nuclear factor kappa B (NF-kB), oxidative stress (activation of Nerf2) and the activity of the endothelin receptor. In particular, it relates to useful enriched fractions and pharmaceutical compositions from wax myrtle for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an inhibitor of oxidative stress (activation of Nerf2), NF-kB inhibitor and an endothelin receptor inhibitor. The present invention also relates to compositions from wax myrtle useful to inhibit cell proliferation and for the induction of apoptosis.

Abstract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Maytenus abenfolia to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Maytenus abenfolia suspended in the vehicle. A method of making an extract of Maytenus abenfolia may comprise creating a component solution by treating Maytenus abenfolia material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Maytenus abenfolia may comprise components extracted using various solvents.

Abstract: A method of inhibiting COX-2, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Campsiandra angustifolia to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Campsiandra angustifolia suspended in the vehicle. A method of making an extract of Campsiandra angustifolia may comprise creating a component solution by treating Campsiandra angustifolia material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Campsiandra angustifolia may comprise components extracted using various solvents.

Abstract: A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Salacia cuspidata to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Salacia cuspidata suspended in the vehicle. A method of making an extract of Salacia cuspidata may comprise creating a component solution by treating Salacia cuspidata material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Salacia cuspidata may comprise components extracted using various solvents.

Abstract: The present invention relates to the use of certain novel compositions from clary sage (Salvia sclarea) which are inhibitors of nuclear factor kappa B (NF-?B), oxidative stress (activation of Nerf2) and the activity of the endothelin receptor. In particular, it relates to useful enriched fractions and pharmaceutical compositions from clary sage for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an inhibitor of oxidative stress (activation of Nerf2), NF-?B inhibitor and an endothelin receptor inhibitor. The present invention also relates to compositions from clary sage useful to inhibit cell proliferation and for the induction of apoptosis.

Abstract: A method for the identification of a composition useful in the treatment of an overweight or obese person to reduce the person's body mass index is provided which comprises obtaining an extract of an ethnobotanical plant, and evaluating the activity of the extract in an assay. A composition is described for treating patient conditions made up of C. grandis standardized extract (AdipoCleave™) with cucurbitacins B and D as active ingredients, Cephalandrol, Cephalandrine A and B, and like compounds and cucurbitacins. The composition is effective to maintain normal blood sugar and normal levels of non-enzymatic protein glycosilation.

Abstract: The present invention relates to the use of certain novel myriceric acid derivatives of the formula: which are inhibitors of nuclear factor kappa B (NF-?B) and inhibit the activity of the endothelin receptor for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an NF-?B inhibitor and an endothelin receptor inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.